• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Avation Medical Announces Appointment of Chief Marketing Officer to Executive Leadership Team

    4/13/22 9:59:00 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care
    Get the next $TCMD alert in real time by email

    Avation Medical appoints Darren Wennen, a medical industry veteran, as Chief Marketing Officer in anticipation of commercialization of its wearable neuromodulation system to treat OAB and UUI.

    COLUMBUS, Ohio, April 13, 2022 /PRNewswire/ -- Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced the appointment of Darren Wennen as its Chief Marketing Officer.  He will be responsible for all aspects of marketing, sales operations and customer care as the Company prepares to bring its novel wearable therapy and digital support system to market.  

    Avation Logo (PRNewsfoto/Avation Medical)

    Avation Medical appoints CMO in anticipation of launch of wearable neuromodulation system to treat OAB & UUI

    "I am thrilled to welcome Darren to Avation Medical.  His commercial experience and track record of growth is the ideal addition to our team as we prepare to launch our category-changing technology for patients suffering from OAB and UUI," said Jill Schiaparelli, Avation's CEO.  "Darren joins a strong team of professionals at Avation that is committed to making neuromodulation more accessible to patients suffering from chronic conditions through its wearable therapy and digitally enabled behavioral support platform."  

    "I am very excited about the potential for Avation's easy-to-use wearable therapy system," added Mr. Wennen.  "The 42 million Americans with OAB and UUI have sent a clear message that they want an effective treatment option that does not require surgery, permanent implants or the side-effects of medication. Our system combines non-invasive neuromodulation therapy with a digitally enabled behavioral support system, offering patients a new option that is effective, convenient, and safe."

    Mr. Wennen brings to Avation Medical a demonstrated history of successful product launches and sales growth. Most recently, Mr. Wennen served as VP of Marketing and Clinical Affairs, as well as SVP of Commercial Operations, for Tactile Medical (NASDAQ:TCMD), where he helped to develop an underserved, reimbursement driven DME wearable market in lymphedema, to grow the company to over $200 million in sales and to complete an IPO on NASDAQ. Earlier in his career, Mr. Wennen held leadership roles with Stryker Orthopedics, Gyrus/ACMI (now Olympus), St. Jude Medical (now Abbott) and Sterilmed (a J&J Company).  Mr. Wennen holds an MBA in marketing and international finance from the University of St. Thomas (St. Paul, MN), and a bachelor's degree from the University of Minnesota.

    About Avation Medical

    Avation Medical is an innovative neuromodulation and digital health company with a mission to make neuromodulation more accessible to patients across a variety of clinical conditions by eliminating the need for surgery, permanent implants and the side-effects of medications and shifting treatment to the home environment.  The Company's novel platform combines non-invasive neuromodulation therapy with digital health tools to offer a complete therapy and support system across a range of chronic conditions.   The Company's intelligent wearable therapy objectively confirms activation of the target nerve, sets a personalized therapeutic range for each patient, and delivers clinically effective therapy in just 30 minutes.   The Company's first product, a wearable neuromodulation and digitally enabled behavior support system for OAB and UUI, is currently available for investigational use only and is not FDA cleared.

    Corporate Contact:

    Jackie Gerberry 

    Senior Director 

    [email protected] 

    www.Avation.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avation-medical-announces-appointment-of-chief-marketing-officer-to-executive-leadership-team-301524971.html

    SOURCE Avation Medical

    Get the next $TCMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCMD

    DatePrice TargetRatingAnalyst
    5/6/2025$14.00Overweight → Neutral
    Piper Sandler
    2/19/2025$23.00 → $18.00Buy → Neutral
    B. Riley Securities
    11/5/2024Outperform → Perform
    Oppenheimer
    11/5/2024Buy → Neutral
    BTIG Research
    9/26/2024$23.00Buy
    B. Riley Securities
    More analyst ratings

    $TCMD
    Financials

    Live finance-specific insights

    See more
    • Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results

      MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024Repurchased $10.0 million of stock under the Company's share repurchase programExpanded launch of

      5/5/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025

      MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 5, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13752588. A live webcast of the call will also be provided on the

      4/21/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 10% year-over-year to $85.6 millionGross margin of 75% versus 72% in Q4 2023Net income of $9.7 million versus $8.2 million in Q4 2023Adjusted EBITDA of $16.2 million versus $15.4 million in Q4 2023Expanded launch of Nimbl to include patients with lower extremity lymphedemaAppointed Laura King to Board of

      2/18/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Tactile Systems downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Tactile Systems from Overweight to Neutral and set a new price target of $14.00

      5/6/25 8:04:03 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Systems downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Tactile Systems from Buy to Neutral and set a new price target of $18.00 from $23.00 previously

      2/19/25 7:05:55 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Systems downgraded by Oppenheimer

      Oppenheimer downgraded Tactile Systems from Outperform to Perform

      11/5/24 7:15:44 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $TCMD
    SEC Filings

    See more
    • Tactile Systems Technology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

      5/9/25 4:56:54 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Tactile Systems Technology Inc.

      S-8 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

      5/7/25 3:41:56 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Tactile Systems Technology Inc.

      10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

      5/5/25 4:06:46 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results

      MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024Repurchased $10.0 million of stock under the Company's share repurchase programExpanded launch of

      5/5/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Medical to Release First Quarter of Fiscal Year 2025 Financial Results on May 5, 2025

      MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 5, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13752588. A live webcast of the call will also be provided on the

      4/21/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Medical to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

      MINNEAPOLIS, March 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which is being virtually held from March 17th – 20th. Management will participate in a virtual presentation on Tuesday, March 18th at 12:00 p.m. Eastern Time. A live audio webcast of the presentation will be accessible under the "Events & Webcasts" section of the Company's investor relations website at http://investors.tactilemedical.com. An archive of the w

      3/5/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Director Burke William W was granted 16,078 shares and sold $31,911 worth of shares (3,300 units at $9.67), increasing direct ownership by 36% to 48,520 units (SEC Form 4)

      4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

      5/9/25 4:28:47 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Director Asbury Valerie L. was granted 16,078 shares, increasing direct ownership by 49% to 48,822 units (SEC Form 4)

      4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

      5/9/25 4:28:20 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Director Huggenberger Raymond was granted 16,078 shares, increasing direct ownership by 40% to 56,320 units (SEC Form 4)

      4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

      5/9/25 4:27:48 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

      SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/13/24 7:29:11 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tactile Systems Technology Inc.

      SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/13/24 5:04:27 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tactile Systems Technology Inc.

      SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/8/24 3:21:42 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $TCMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Tactile Medical Appoints Laura King to Board of Directors

      MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company's Board of Directors ("Board") and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE

      1/13/25 8:00:00 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • LifeLens Technologies Expands Executive Leadership Team and Board of Directors

      PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors: Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive OfficerBrent A. Moen as Chief Financial OfficerRichard J. Buchholz as a member of the Board of Directors "With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens tea

      11/8/23 7:30:00 AM ET
      $INSP
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Tactile Medical Appoints Vindell Washington, M.D. to Board of Directors

      MINNEAPOLIS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Vindell Washington, M.D. to the Company's Board of Directors ("Board"), effective October 2, 2023. "We are pleased to welcome Dr. Washington to Tactile Medical, who joins our Board with over 30 years of experience in the healthcare industry," said Bill Burke, Chairman of the Board of Tactile Medical. "We will benefit from his breadth of experience in medicine, technology and policy, as well as his expertise in advising healthcare companies on their clinical s

      10/2/23 4:05:00 AM ET
      $TCMD
      Medical/Dental Instruments
      Health Care